Novo Nordisk Rules Out Big M&A for Now as It Works to Steady Its Pipeline

Novo Nordisk, maker of the blockbuster obesity drug Wegovy, is not looking to make a big acquisition right now, its chief executive said — a notable stance for a company facing mounting competitive pressure.

Speaking after second-quarter results, CEO Maziar “Mike” Doustdar — about a year into the job — said Novo is “not currently in a position to pursue large-scale M&A”, and will focus instead on smaller bolt-on deals.

“I’m a person who never starts with a no” to transformative deals one day, he said, “but you have to be in a very different situation than Novo Nordisk is in today.”

Why the caution

Novo has hit a rough patch. Its experimental drug ziltivekimab failed a Phase 3 trial, and its next-generation obesity candidate CagriSema fell short against Eli Lilly’s tirzepatide.

Sales need stabilising: in the second quarter, oral Wegovy sales came in about 20% below analyst expectations, even as Lilly presses its advantage in the obesity and diabetes market.

What the CagriSema result actually meant

That disappointment deserves specifying, because it was strategically more consequential than a single trial miss.

CagriSema combines semaglutide with cagrilintide, an amylin analogue, and the combination was Novo’s answer to the fact that tirzepatide — which hits two receptors rather than one — produces more weight loss than semaglutide alone.

The bet was that adding a second mechanism would restore parity or better. Falling short means the competitive gap in efficacy persists into the next generation, and Novo does not have an obvious answer to it in late-stage development.

The ziltivekimab failure compounds that, since it was a diversification away from metabolic disease — an anti-inflammatory approach to cardiovascular risk — and its loss narrows the pipeline back toward the area where competition is fiercest.

Why a large acquisition is the conventional response

Declining large M&A under these conditions is the noteworthy part, because pipeline setbacks are exactly what usually triggers a major purchase.

The logic is straightforward: internal research operates on its own timeline and cannot be accelerated by spending, while buying a company with a late-stage asset converts capital into pipeline immediately.

Doustdar’s phrasing — “not currently in a position” — is careful, and it suggests capability rather than appetite. A company whose share price has fallen has weaker currency for a stock-funded deal, and one absorbing a series of setbacks may reasonably doubt its capacity to integrate a large acquisition while fixing its own operations.

The deals it has and has not done

Novo is not sitting still on smaller deals: in October 2025 it acquired liver-disease specialist Akero Therapeutics for $5.2 billion. But it also lost a roughly $10 billion deal for Metsera to Pfizer.

Calling a $5.2 billion acquisition a bolt-on is a signal in itself about the scale at which this company operates. The Akero deal also has strategic coherence — metabolic liver disease is adjacent to obesity, shares patients and prescribers, and diversifies without departing from what Novo knows.

The Metsera loss is the more telling event. Being outbid on an obesity asset by a competitor entering the field indicates the pressure Doustdar is describing.

“In every data room”

Doustdar said the company keeps reviewing opportunities — it is “in every data room” — while betting for now on fixing and advancing its own pipeline.

That phrase is doing deliberate work. It signals to investors that the company is not passive and preserves optionality, while committing to nothing. It also signals to targets that Novo remains a potential buyer, which matters for future negotiations.

The strategic risk

Internal turnaround takes years, and the competitive position may not hold that long.

The obesity market is expanding rapidly and being contested now, with oral formulations, next-generation combinations and new mechanisms all arriving in the same period. Market share established during this phase will be difficult to reclaim later, since prescribers and payers settle into patterns.

The patent clock behind the urgency

Underlying the strategic discussion is a timetable that constrains every decision Novo makes about its pipeline.

Semaglutide’s core patents begin expiring in major markets over the coming years, earlier in some jurisdictions than others. When they do, generic and biosimilar competition arrives against a product that currently generates the majority of the company’s revenue, and prices for the older formulations fall sharply.

Companies in that position normally respond by moving patients onto a newer, patent-protected product before the cliff arrives — which is exactly what a successful next-generation obesity drug would have enabled. A candidate falling short against a competitor’s existing product does not merely lose a comparison; it weakens the transition plan.

That is the sharper reading of the caution. The question is not only whether Novo can compete on efficacy today, but whether it will have a protected franchise to move its base onto when the current one loses exclusivity — and internal development takes years the clock may not allow.

Waiting is a defensible judgement about what the company can execute. It is also a decision to compete through a formative period with the pipeline it already has. Business news, not investment advice.